Disialoganglioside Directed Immunotherapy of Neuroblastoma

REFERENCES

• Kramer K., Kushner B., Heller G., Cheung N. K. Neuroblastoma metastatic to the central nervous system. The Memorial Sloan-Kettering Cancer Center Experience and A literature review. Cancer 2001; 91(8)1510–1519
   Google Scholar
• Matthay K. K., Villablanca J. G., Seeger R. C. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N. Engl. J. Med. 1999; 341(16)1165–1173
   PubMed Web of Science ®Google Scholar
• Rousseau R. F., Brenner M. K. Vaccine therapies for pediatric malignancies. Cancer J. 2005; 11(4)331–339
   PubMed Web of Science ®Google Scholar
• Caruso D. A., Orme L. M., Amor G. M. Results of a phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with stage 4 neuroblastoma. Cancer 2005; 103(6)1280–1291
   PubMed Web of Science ®Google Scholar
• Lipinski M., Hirsch M. R., Deagostini-Bazin H., Yamada O., Tursz T., Goridis C. Characterization of neural cell adhesion molecules (NCAM) expressed by Ewing and neuroblastoma cell lines. Int. J. Cancer 1987; 40(1)81–86
   PubMed Web of Science ®Google Scholar
• Grunberg J., Novak-Hofer I., Honer M. In vivo evaluation of 177Lu-and 67/64Cu-labeled recombinant fragments of antibody chCE7 for radioimmunotherapy and PET imaging of L1-CAM-positive tumors. Clin. Cancer Res. 2005; 11(14)5112–5120
   PubMed Web of Science ®Google Scholar
• Modak S., Kramer K., Gultekin S. H., Guo H. F., Cheung N. K. Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer Res. 2001; 61(10)4048–4054
   PubMed Web of Science ®Google Scholar
• Smolarz K., Waters W., Sieverts H. Immunoscintigraphy with Tc-99m-labeled monoclonal antibody BW575 compared with I-123 MIBG scintigraphy in neuroblastoma. Radiology 1989; 173: 152–153
   Google Scholar
• Hakomori S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv. Exp. Med. Biol. 2001; 491: 369–402
   PubMed Web of Science ®Google Scholar
• Bullens R. W., O'Hanlon G. M., Wagner E. Roles of complex gangliosides at the neuromuscular junction. Ann. NY Acad. Sci. 2003; 998: 401–403
   PubMed Web of Science ®Google Scholar
• Hakomori S., Igarashi Y. Functional role of glycosphingolipids in cell recognition and signaling. J. Biochem (Tokyo.) 1995; 118(6)1091–1103
   PubMed Web of Science ®Google Scholar
• Helling F., Livingston P. O. Ganglioside conjugate vaccines. Immunotherapy against tumors of neuroectodermal origin. Mol. Chem. Neuropathol. 1994; 21(2–3)299–309
   PubMedGoogle Scholar
• Furukawa K., Soejima H., Niikawa N., Shiku H. Genomic organization and chromosomal assignment of the human B1,4-N-acetylgalactosaminyltransferase gene. J. Biol. Chem. 1996; 271: 20836–20844
   PubMed Web of Science ®Google Scholar
• Wu Z., Schwartz E., Seeger R. C., Ladisch S. Expression of GD2 ganglioside by untreated primary human neuroblastomas. Cancer Res. 1986; 46: 440–443
   PubMed Web of Science ®Google Scholar
• Kramer K., Gerald W. L., Kushner B. H., Larson S. M., Hameed M., Cheung N. K. Disialoganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma. Medical Pediatric Oncology. 2001; 36: 194–196
   PubMedGoogle Scholar
• Schulz G., Cheresh D. A., Varki N. M., Yu A., Staffileno L. K., Reisfeld R. A. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res. 1984; 44: 5914–5920
   PubMed Web of Science ®Google Scholar
• Kushner B. H., Cheung I. Y., Kramer K., Modak S., Cheung N. K. High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: Broad implications for immunotherapy. Pediatr. Blood Cancer 2006, forthcoming
   Web of Science ®Google Scholar
• Imai M., Landen C., Ohta R., Cheung N. K., Tomlinson S. Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic Cancer. Cancer Res. 2005; 65(22)10562–10568
   PubMed Web of Science ®Google Scholar
• Lode H. N., Xiang R., Varki N. M., Dolman C. S., Gillies S. D., Reisfeld R. A. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J. Natl. Cancer Inst. 1997; 89: 1586–1594
   PubMed Web of Science ®Google Scholar
• Kushner B. H., Cheung N. K. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood 1989; 73(7)1936–1941
   PubMed Web of Science ®Google Scholar
• Lo Piccolo M. S., Cheung N. K., Cheung I. Y. GD2 synthase: a new molecular marker for detecting neuroblastoma. Cancer 2001; 92(4)924–931
   PubMed Web of Science ®Google Scholar
• Cheung I. Y., Lo Piccolo M. S., Kushner B. H., Cheung N. K. Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma. J. Clin. Oncol. 2003; 21(20)3853–3858
   PubMed Web of Science ®Google Scholar
• Cheung I. Y., Sahota A., Cheung N. K. Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysis. Cancer 2004; 101(10)2303–2308
   PubMed Web of Science ®Google Scholar
• Cheung N. K., Saarinen U., Neely J., Landmeier B., Donovan D., Coccia P. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res. 1985; 45: 2642–2649
   PubMed Web of Science ®Google Scholar
• Cheung N. K.V., Walter E. I., Smith-Mensah W. H., Ratnoff W. D., Tykocinski M. L., Medof M. E. Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J. Clin. Invest. 1988; 81: 1122–1128
   PubMed Web of Science ®Google Scholar
• Munn D. H., Cheung N. K. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity (ADCC) against human melanoma. Cancer Res. 1987; 47: 6600–6605
   PubMed Web of Science ®Google Scholar
• Munn D. H., Cheung N. K. Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficient antibody-mediated antitumor cytotoxicity not detected by isotope release assays. J. Exp. Med. 1989; 170: 511–526
   PubMed Web of Science ®Google Scholar
• Kushner B. H., Cheung N. K. Absolute requirement of CD11/CD18 adhesion molecules, FcRII and the phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil antihuman tumor cytotoxicity. Blood 1992; 79(6)1484–1490
   PubMed Web of Science ®Google Scholar
• Hong F., Yan J., Baran J. T. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J. Immunol. 2004; 173(2)797–806
   PubMed Web of Science ®Google Scholar
• Cheung N., Modak S. Oral (1-3,(1-4)-beta-glucan syngergizes with anti-ganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin. Cancer Res. 2002; 8: 1217–1223
   PubMed Web of Science ®Google Scholar
• Cheung N. K., Modak S., Vickers A., Knuckles B. Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol. Immunother. 2002; 51(10)557–564
   PubMed Web of Science ®Google Scholar
• Cheung N. K., Lazarus H., Miraldi F. D. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J. Clin. Oncol. 1987; 5(9)1430–1440
   PubMed Web of Science ®Google Scholar
• Cheung N. K., Kushner B. H., Yeh S. D., Larson S. M. 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study. Int. J. Oncol. 1998; 12(6)1299–1306
   PubMed Web of Science ®Google Scholar
• Kushner B. H., Kramer K., Cheung N. K.V., Phase I I. trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J. Clin. Oncol. 2001; 19: 4189–4194
   PubMed Web of Science ®Google Scholar
• Stein J., Strandjord S., Saarinen U. M. In vitro treatment of autologous bone marrow from neuroblastoma patients with anti-G{-D2} monoclonal antibody and human complement: a pilot study. Advances in Neuroblastoma Research, A. E. Evans, G. J. D'Angio, A. G. Knudson, R. C. Seeger. Alan Liss, New York 1988; 237–248
   Google Scholar
• Brodeur G. M., Pritchard J., Berthold F. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J. Clin. Oncol. 1993; 11(8)1466–1477
   PubMed Web of Science ®Google Scholar
• Cheung N. K., Kushner B. H., Cheung I. Y. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J. Clin. Oncol. 1998; 16(9)3053–3060
   PubMed Web of Science ®Google Scholar
• Kushner B., Kramer K., Modak S., Cheung N. K. Anti-GD2 monoclonal antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for primary refractory neuroblastoma (NB) in bone marrow. Advances in Neuroblastoma Research: Eleventh Conference. 2006, Abstr. 303
   Google Scholar
• Cheung I. Y., Lo Piccolo M. S., Kushner B. H., Kramer K., Cheung N. K. Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma. J. Clin. Oncol. 2003; 21(6)1087–1093
   PubMed Web of Science ®Google Scholar
• Beiske K., Ambros P. F., Burchill S. A., Cheung I. Y., Swerts K. Detecting minimal residual disease in neuroblastoma patients-the present state of the art. Cancer Lett. 2005; 228(1–2)229–240
   PubMed Web of Science ®Google Scholar
• Lin Y., Kushner B., Modak S. Pre-Administration of Heat-Modified 3F8 reduces 3F8 Infusion-Associated pain In patients with neuroblastoma. Advances in Neuroblastoma Research: Eleventh Conference. 2006, Abstr. 328
   Google Scholar
• Cheung N. K., Cheung I. Y., Canete A. Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival. Cancer Res. 1994; 54(8)2228–2233
   PubMed Web of Science ®Google Scholar
• Modak S., Kushner B., Kramer K., Vickers A., Cheung N. K. Combination of anti-GD2 antibody 3F8 and barley-derived (1→3), 1→4) B-D-glucan: phase i study in patients with resistant neuroblastoma. Advances in Neuroblastoma Research: eleventh conference. 2006, Abstr. 326
   Google Scholar
• Rill D. R., Santana V. M., Roberts W. M. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994; 84: 380–383
   PubMed Web of Science ®Google Scholar
• Cheung I. Y., Lo Piccolo M. S., Collins N., Kushner B. H., Cheung N. K. Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8. Cancer 2002; 94(11)3042–3048
   PubMed Web of Science ®Google Scholar
• van Sorge N. M., van der Pol W. L., van de Winkel J. G., Fcγ R. polymorphisms: implications for function, disease susceptibility and immunotherapy. Tissue Antigens 2003; 61(3)189–202
   PubMed Web of Science ®Google Scholar
• Ravetch J. V., Bolland S. IgG Fc receptors. Annu Rev Immunol. 2001; 19: 275–290
   PubMed Web of Science ®Google Scholar
• Cheung N. K., Sowers R., Vickers A. J., Cheung I. Y., Kushner B. H., Gorlick R. FCGR2A polymorphism is correlated with Clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J. Clin. Oncol. 2006; 24(18)2885–2890
   PubMed Web of Science ®Google Scholar
• Mujoo K., Kipps T. J., Yang H. M. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Cancer Res. 1989; 49(11)2857–2861
   PubMed Web of Science ®Google Scholar
• Raffaghello L., Marimpietri D., Pagnan G. Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse. Cancer Lett. 2003; 197(1–2)205–209
   PubMed Web of Science ®Google Scholar
• Slart R., Yu A. L., Yaksh T. L., Sorkin L. S. An animal model of pain produced by systemic administration of an immunotherapeutic anti-ganglioside antibody. Pain 1997; 69(1–2)119–125
   PubMed Web of Science ®Google Scholar
• Handgretinger R., Baader P., Dopfer R. A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol. Immunother. 1992; 35(3)199–204
   PubMed Web of Science ®Google Scholar
• Murray J. L., Cunningham J. E., Brewer H., Phase I. trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J. Clin. Oncol. 1994; 12(1)184–193
   PubMed Web of Science ®Google Scholar
• Uttenreuther-Fischer M. M., Huang C. S., Reisfeld R. A., Yu A. L. Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients. Cancer Immunol. Immunother. 1995; 41(1)29–36
   PubMed Web of Science ®Google Scholar
• Frost J. D., Hank J. A., Reaman G. H. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma. Cancer 1997; 80: 317–333
   PubMed Web of Science ®Google Scholar
• Gillies S. D., Lo K.-M., Wesolowski J. High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. J. Immunol Methods. 1989; 125: 191–202
   PubMed Web of Science ®Google Scholar
• Barker E., Mueller B. M., Handgretinger R., Herter M., Yu A. L., Reisfeld R. A. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res. 1991; 51: 144–149
   PubMed Web of Science ®Google Scholar
• Barker E., Reisfeld R. A. A mechanism for neutrophil-mediated lysis of human neuroblastoma cells. Cancer Res. 1993; 53(2)362–367
   PubMed Web of Science ®Google Scholar
• Mueller B. M., Romerdahl C. A., Gillies S. D., Reisfeld R. A. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J. Immunol. 1990; 144(4)1382–1386
   PubMed Web of Science ®Google Scholar
• Handgretinger R., Anderson K., Lang P. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur. J. Cancer 1995; 31A(2)261–267
   PubMed Web of Science ®Google Scholar
• Yu A., Uttenreuther-Fischer M., Huang C.-S. I Phase trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J. Clin. Oncol. 1998; 16: 2169–2180
   PubMed Web of Science ®Google Scholar
• Kremens B., Hero B., Esser J. Ocular symptoms in children treated with human-mouse chimeric anti-GD2 mAb ch14.18 for neuroblastoma. Cancer Immunol. Immunother. 2002; 51(2)107–110
   PubMed Web of Science ®Google Scholar
• Uttenreuther-Fischer M. M., Huang C. S., Yu A. L. Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients. Cancer Immunol. Immunother. 1995; 41(6)331–338
   PubMed Web of Science ®Google Scholar
• Uttenreuther-Fischer M. M., Kruger J. A., Fischer P. Molecular characterization of the anti-idiotypic immune response of a relapse-free neuroblastoma patient following antibody therapy: a possible vaccine against tumors of neuroectodermal origin?. J. Immunol. 2006; 176(12)7775–7786
   PubMed Web of Science ®Google Scholar
• Simon T., Hero B., Faldum A. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J. Clin. Oncol. 2004; 22(17)3549–3557
   PubMed Web of Science ®Google Scholar
• Simon T., Hero B., Faldum A. Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy. Klin. Padiatr. 2005; 217(3)147–152
   PubMed Web of Science ®Google Scholar
• Ozkaynak M. F., Sondel P. M., Krailo M. D. I Phase study of chimeric human/murine antiganglioside GD2 monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma inmmediately after hematopoietic stem-cell transplantation: a children's cancer group study. J. Clin. Oncol. 2000; 18: 4077–4085
   PubMed Web of Science ®Google Scholar
• Zeng Y., Fest S., Kunert R. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol. Immunol. 2005; 42(11)1311–1319
   PubMed Web of Science ®Google Scholar
• Gillies S. D., Reilly E. B., Lo K. M., Reisfeld R. A. Antibody-targeted interleukin-2 stimulates T-cell killing of autologous tumor cells. Proc. Natl. Acad. Sci. USA 1992; 89: 1428–1432
   PubMed Web of Science ®Google Scholar
• Hank J. A., Surfus J. E., Gan J. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2). Clin. Cancer Res. 1996; 2(12)1951–1959
   PubMed Web of Science ®Google Scholar
• Pancook J. D., Becker J. C., Gillies S. D., Reisfeld R. A. Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2. Cancer Immunol. Immunother. 1996; 42(2)88–92
   PubMed Web of Science ®Google Scholar
• King D. M., Albertini M. R., Schalch H., Phase I. clinical trial of the immunocytokine EMD 273063 in melanoma patients. J. Clin. Oncol. 2004; 22(22)4463–4473
   PubMed Web of Science ®Google Scholar
• Osenga K., Hank J., Albertini M. R. A phase I trial of immunocytokine HU14.18-IL12 in children with recurrent or refractory neuroblastoma and other GD2 positivie malignancies: a study of the children's oncology group. Proc. ISBTC 2004; 50
   Google Scholar
• Hank J., Gan J., Sternberg A., Ryu H., Gilllies S., Sondel P. The functional effects of anti-hu14.18 antibody activity found in the serum of patients following infusion of immunocytokine (ic) hu14.18-il2 for treatment of neuroblastoma. Advances in Neuroblastoma Research: eleventh conference. 2006, Abstr. 223
   Google Scholar
• Yeh S. D., Larson S. M., Burch L. Radioimmunodetection of neuroblastoma with iodine-131-3F8: correlation with biopsy, iodine-131-metaiodobenzylguanidine (MIBG) and standard diagnostic modalities. J. Nucl Med. 1991; 32: 769–776
   PubMed Web of Science ®Google Scholar
• Larson S. M., Pentlow K. S., Volkow N. D. PET scanning of iodine-124-3F8 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. J. Nucl Med. 1992; 33: 2020–2023
   PubMed Web of Science ®Google Scholar
• Cheung N. K., Kushner B. H., Kramer K. Monoclonal antibody-based therapy of neuroblastoma. Hematol Oncol Clin. North Am. 2001; 15(5)853–866
   PubMed Web of Science ®Google Scholar
• Cheung N. K., Pentlow K., Graham M. C., Yeh S. D.J., Finn R. D., Larson S. M. Radioimmunotherapy of human neuroblastoma using monoclonal antibody 3F8. Fifth International Radiopharmaceutical Dosimetry Symposium. Oak Ridge Associated Universities, Oak Ridge, TN 1992; 95–112
   Google Scholar
• Modak S., Cheung N. K. Antibody-based targeted radiation to pediatric tumors. J. Nucl Med. 2005; 46: 157S–163S
   PubMed Web of Science ®Google Scholar
• Larson S. M., Divgi C., Sgouros G., Cheung N. K.C., Scheinberg D. A. Monoclonal antibodies: basic prniciples-Radioisotope conjugates. Biologic Therapy of Cancer-Principles and Practice, V T De Vita, S Hellman, S A Rosenberg. J.B. Lippincott Co., Philadelphia 2000; 396–412
   Google Scholar
• Cheung N. K., Rooney C. Principles of immune and cellular therapy. Principles and Practice of Pediatric Oncology, 4th ed., P. A. Pizzo, D. G. Poplack. J.B. Lippincott Company, Philadelphia 2002; 381–408
   Google Scholar
• Kramer K., Cheung N. K., Humm J. Pharmacokinetics and acute toxicology of intraventricular 131 I-monoclonal antibody targeting disialoganglioside in non-human primates. J. Neurooncol. 1997; 35(2)101–111
   PubMed Web of Science ®Google Scholar
• Kramer K., Cheung N. K., Humm J. L. Targeted radioimmunotherapy for leptomeningeal cancer using (131)I-3F8. Med. Pediatr Oncol. 2000; 35(6)716–718
   PubMedGoogle Scholar
• Murray J. L., Cunningham J. E., Brewer H., Phase I. trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J. Clin. Oncol. 1994; 12: 184–193
   PubMed Web of Science ®Google Scholar
• Reuland P., Geiger L., Thelen M. H. Follow-up in neuroblastoma: comparison of metaiodobenzylguanidine and a chimeric anti-GD2 antibody for detection of tumor relapse and therapy response. J. Pediatr. Hematol. Oncol. 2001; 23(7)437–442
   PubMed Web of Science ®Google Scholar
• Helling F., Zhang S., Shang A. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res. 1995; 55(13)2783–2788
   PubMed Web of Science ®Google Scholar
• Cheung N. K., Guo H. F., Heller G., Cheung I. Y. Induction of Ab3 and Ab3′ antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma. Clin. Cancer Res. 2000; 6(7)2653–2660
   PubMed Web of Science ®Google Scholar
• Foon K. A., John W. J., Chakraborty M. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J. Clin. Oncol. 1999; 17: 2889–2895
   PubMed Web of Science ®Google Scholar
• Alfonso M., Diaz A., Hernandez A. M. An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J. Immunol. 2002; 168(5)2523–2529
   PubMed Web of Science ®Google Scholar
• Ragupathi G., Livingston P. O., Hood C. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin. Cancer Res. 2003; 9(14)5214–5220
   PubMed Web of Science ®Google Scholar
• Zeytin H. E., Tripathi P. K., Bhattacharya-Chatterjee M., Foon K. A., Chatterjee S. K. Construction and characterization of DNA vaccines encoding the single-chain variable fragment of the anti-idiotype antibody 1A7 mimicking the tumor-associated antigen disialoganglioside GD2. Cancer Gene Therapy 2000; 7: 1426–1436
   PubMed Web of Science ®Google Scholar
• Yu A. Promising results of a pilot trial of a GD2 directed anti-idiotypic antibody as a vaccine for high risk neuroblastoma. Proc. ASCO Meeting. 2004, Abst. No. 8511
   Google Scholar
• Batova A., Kamps A., Gillies S. D., Reisfeld R. A., Yu A. L. The ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro. Clin. Cancer Res. 1999; 5: 4259–4263
   PubMed Web of Science ®Google Scholar
• Manzke O., Russello O., Leenen C., Diehl V., Bohlen H., Berthold F. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin Aconjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies. Med. Pediatr Oncol. 2001; 36(1)185–189
   PubMedGoogle Scholar
• Lode H. N., Reisfeld R. A., Handgretinger R., Nicolaou K. C., Gaedicke G., Wrasidlo W. Targeted therapy with a novel enediyene antibiotic calicheamicin theta(I)1 effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma. Cancer Res. 1998; 58(14)2925–2928
   PubMed Web of Science ®Google Scholar
• Brignole C., Pagnan G., Marimpietri D. Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment. Cancer Lett. 2003; 197(1–2)231–235
   PubMed Web of Science ®Google Scholar
• Raffaghello L., Pagnan G., Pastorino F. Immunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma. Cancer Lett. 2003; 197(1–2)151–155
   PubMed Web of Science ®Google Scholar
• Brignole C., Marimpietri D., Gambini C., Allen T. M., Ponzoni M., Pastorino F. Development of Fab' fragments of anti-GD(2) immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma. Cancer Lett. 2003; 197(1–2)199–204
   PubMed Web of Science ®Google Scholar
• Zeng Y., Jiang J., Huebener N. Fractalkine gene therapy for neuroblastoma is more effective in combination with targeted IL-2. Cancer Lett. 2005; 228(1–2)187–193
   PubMed Web of Science ®Google Scholar
• Otto M., Barfield R. C., Martin W. J. Combination immunotherapy with Clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma. Clin. Cancer Res. 2005; 11(23)8486–8491
   PubMed Web of Science ®Google Scholar
• Miederer M., McDevitt M. R., Borchardt P. Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha emitting atomic nanogenerators targeting Ganglioside GD2. Clin. Cancer Res. 2004; 10(20)6985–6992
   PubMed Web of Science ®Google Scholar
• Cheung N.-K. V., Modak S., Lin Y. K. Single chain Fv-streptavidin substantially improved therapeutic index in multi-step targeting directed at disialoganglioside GD2. J. Nucl. Med. 2004; 45(5)867–877
   PubMed Web of Science ®Google Scholar
• Forster-Waldl E., Riemer A. B., Dehof A. K. Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen. Mol. Immunol. 2005; 42(3)319–325
   PubMed Web of Science ®Google Scholar
• Bolesta E., Kowalczyk A., Wierzbicki A. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses. Cancer Res. 2005; 65(8)3410–3418
   PubMed Web of Science ®Google Scholar
• Krause A., Guo H. F., Latouche J. B., Tan C., Cheung N. K., Sadelain M. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J. Exp. Med. 1998; 188(4)619–626
   PubMed Web of Science ®Google Scholar
• Rossig C., Bollard C. M., Nuchtern J. G., Merchant D. A., Brenner M. K. Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int. J. Cancer 2001; 94(2)228–236
   PubMed Web of Science ®Google Scholar